FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年9月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份 ...

Investment Rating - The report maintains a "Buy" rating for the company, anticipating significant growth in the next 6-12 months [4][12]. Core Insights - The company achieved a revenue of 1.495 billion RMB in the first half of 2025, representing a year-on-year increase of 9.5%, and an adjusted net profit of 170 million RMB, up 15.2% year-on-year [2]. - The company is expanding its operations steadily, with offline medical institution revenue growing by 11.1% to 1.367 billion RMB, and total patient visits increasing by 15.3% to 2.747 million in the same period [2]. - The company has established a strong doctor resource barrier, with a total of 41,743 doctors, including 648 new offline practicing doctors, marking a 23.5% year-on-year increase [3]. - The company's in-house formulations business is experiencing rapid growth, with a revenue increase of 209% year-on-year, enhancing the revenue structure and reducing policy risk [3]. Summary by Sections Performance Review - In the first half of 2025, the company reported a revenue of 1.495 billion RMB, a 9.5% increase year-on-year, and a net profit attributable to shareholders of 152 million RMB, reflecting a 41.9% year-on-year growth [2]. Operational Analysis - The company is expanding its network, operating 84 medical institutions globally, with 83 in mainland China and 1 in Singapore, and has added 5 new self-built medical institutions in the first half of 2025 [2]. - Customer retention remains high, with a repeat visit rate of 69.3% [2]. - The company has formed partnerships with 37 medical alliance units, enhancing the supply of quality medical resources [2]. AI Application and Growth - The company has made significant progress in AI applications, launching its first "National Medicine AI Avatar" in June 2025, with a total of 10 avatars covering 8 core specialties by August [3]. - The introduction of the "AI Health Assistant" aims to improve patient experience and address the bottleneck in quality medical resource supply [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 410 million RMB, 524 million RMB, and 669 million RMB for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 34%, 28%, and 28% [4]. - The earnings per share (EPS) are expected to be 1.74 RMB, 2.22 RMB, and 2.84 RMB for the same years, with corresponding price-to-earnings (PE) ratios of 19, 15, and 12 [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][9] Core Views - The company's performance in the first half of 2025 met expectations, with revenue of 1.495 billion yuan (+9.52%) and net profit attributable to shareholders of 152 million yuan (+41.9%) [3][9] - The offline business showed steady growth, with a revenue increase of 11.1% to 1.37 billion yuan, driven by new acquisitions and existing business growth [5] - The company is actively embracing AI technology, having launched its first "National Medicine AI Avatar" in June 2025, with a total of 10 avatars covering eight core traditional Chinese medicine specialties by August [8][9] Financial Performance - The company achieved a gross profit margin of 30.6% (+1.2 percentage points) and a net profit margin of 10.1% (+2.3 percentage points) in the first half of 2025 [6] - The company has expanded its network to 83 medical institutions across 20 cities in China, with one institution in Singapore as of June 30, 2025 [7] - The adjusted net profit for 2025 is forecasted at 398 million yuan, with subsequent years projected at 492 million yuan in 2026 and 588 million yuan in 2027 [9][10] Market Outlook - The demand for traditional Chinese medicine services is strong, supported by favorable policies, indicating a period of rapid growth for the industry [9] - The company is positioned as a leading chain in the traditional Chinese medicine service sector, with significant long-term growth potential due to its brand, talent, and resource advantages [9]

Investment Rating - The report maintains a "Buy" rating for the company [7][8]. Core Views - The company's revenue for 1H25 increased by 9.5% year-on-year to 1.49 billion RMB, while net profit rose by 41.6% to 150 million RMB, indicating strong performance driven by robust offline demand [1][7]. - The management has adjusted the 2025 revenue growth forecast to 10%-15% from the previous 25%, citing changes in the macro environment [1][7]. - The company is expected to return to a revenue growth rate of over 20% in 2026 [1]. Financial Summary - For FY25E, the company is projected to achieve sales revenue of 3.445 billion RMB, reflecting a year-on-year growth of 14.0% [2][8]. - Adjusted net profit for FY25E is estimated at 460 million RMB, with a growth rate of 15.0% [2][8]. - The adjusted earnings per share (EPS) for FY25E is forecasted to be 1.95 RMB [2][8]. Price Target and Valuation - The target price is set at 48.28 HKD, down from a previous target of 52.75 HKD, representing a potential upside of 48.6% from the current stock price of 32.50 HKD [3][7]. - The discounted cash flow (DCF) valuation indicates a per-share value of 48.28 HKD, based on a weighted average cost of capital (WACC) of 10.2% and a perpetual growth rate of 3.0% [10][11]. Shareholder Structure - The largest shareholder is Tu Zhiliang, holding 34.2% of the shares, followed by Ruiyuan Fund with 8.0% [4]. Stock Performance - The stock has shown a decline in absolute returns over the past month (-8.2%) and three months (-11.6%) [5]. Business Development - The company opened 7 new stores in 1H25, bringing the total to 83, and plans to add approximately 15 more stores in 2025 [7]. - The number of doctors in the network increased by 1,501 in 1H25, with a 23.5% year-on-year growth in offline doctors [7]. AI Initiatives - The company has launched AI initiatives, including the first "Famous Doctor AI Avatar," which is expected to generate significant revenue in the future [7]. Shareholder Returns - In 1H25, the company repurchased shares worth 84.69 million HKD, equivalent to 50% of net profit, and declared a mid-term dividend of 75.77 million RMB, also 50% of net profit [7].

查看完整报告 点击注册小程序 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 近期，公司公布2025年中期业绩，2025年上半年公司实现总营业收入14.95亿元，同比增长9.5%；净利润 1.52亿元，同比增长41.6%；经营活动现金流3.0亿元，同比增长111%。 点评： 业绩稳健增长，盈利能力持续优化 2025年上半年，公司收入稳步增长至14.95亿元，同时盈利能力显著提升，净利润同比增长41.6%至1.52亿 元，主要得益于毛利率的提升及费用的有效管控。2025年上半年，公司毛利率同比提升1.2个百分点至 30.6%；销售费用率为11.8%，同比保持稳定；管理费用率同比降低1.8个百分点至6.3%。运营指标方面， 2025年上半年，客户就诊人次增长至274.7万人次，就诊次均消费保持稳定， ...

Group 1 - Jin Chengxin (603979.SH) reported a net profit of 1.111 billion yuan for the first half of 2025, an increase of 81.3% year-on-year. The mining service segment achieved a gross profit of 767 million yuan, down 17% [5] - Guodian Nanrui (600406.SH) achieved an operating income of 24.243 billion yuan in the first half of 2025, a year-on-year increase of 19.54%. The net profit attributable to shareholders was 2.952 billion yuan, up 8.82% [5] - Midea Group (000333.SZ) reported total operating revenue of 252.3 billion yuan for the first half of 2025, a year-on-year increase of 16%. The net profit attributable to shareholders was 26 billion yuan, up 25% [7] - Songcheng Performance (300144.SZ) experienced a decline in revenue, reporting 1.08 billion yuan for the first half of 2025, down 8.3% year-on-year, with a net profit of 400 million yuan, down 27.4% [8] - Gushengtang (2273.HK) achieved total operating revenue of 1.495 billion yuan in the first half of 2025, a year-on-year increase of 9.5%, with a net profit of 152 million yuan, up 41.6% [8] Group 2 - The market is currently favoring large-cap stocks, with significant momentum effects observed [8] - The issuance of credit bonds has decreased, and total transaction volume has also declined [8] - The petrochemical industry faced pressure in the first half of 2025, with attention on oil price expectations and the "anti-involution" process [8] - The chemical industry is gradually recovering, with a focus on the implementation of "anti-involution" policies [8] - Lithium battery capital expenditures exceeded expectations, and Alibaba's financial report has sparked interest in AIDC [8]

Core Viewpoint - The company reported a steady growth in revenue and profit for the first half of 2025, driven by improved gross margins and effective cost control [1] Financial Performance - In the first half of 2025, the company achieved total revenue of 1.495 billion, representing a year-on-year growth of 9.5% [1] - Net profit reached 152 million, showing a significant year-on-year increase of 41.6% [1] - Operating cash flow was 300 million, reflecting a substantial year-on-year growth of 111% [1] - The gross margin improved by 1.2 percentage points to 30.6% [1] - The sales expense ratio remained stable at 11.8%, while the management expense ratio decreased by 1.8 percentage points to 6.3% [1] Operational Metrics - The number of patient visits increased to 2.747 million, with average spending per visit remaining stable [1] - The member customer retention rate was maintained at 85%, indicating strong customer loyalty [1] - The company expanded its national and international presence by establishing 7 new clinics, bringing the total number of offline medical institutions to 83 by the end of June 2025 [1] AI Development - The company is accelerating the development of "AI avatars" of renowned doctors, leveraging extensive and high-quality clinical data [1] - A total of 10 "National Physician AI Avatars" have been launched, covering 8 core specialties including oncology, dermatology, and gastroenterology [1] - The DeepSeek deep learning algorithm enables the replication of top experts' diagnostic capabilities, facilitating the transfer of expertise to junior doctors and enhancing the supply of quality medical resources [1] Profit Forecast and Valuation - The adjusted net profit forecasts for 2025, 2026, and 2027 are 493 million, 594 million, and 708 million respectively [2] - The company is expected to benefit significantly from the aging population, supportive policies in the traditional Chinese medicine sector, and AI empowerment, maintaining a "buy" rating [2]

经营业绩： 澜沧古茶(06911)发布中期业绩，收入1.2亿元 大型客户渠道仍持续增长 农业银行(01288)发布中期业绩 归母净利润1395.1亿元 同比增加2.66% 极兔速递-W(01519)公布中期业绩 经调整净利达1.56亿美元 同比增长147.1% 中银香港(02388)发布中期业绩 股东应占溢利221.2亿港元 同比增加10.54% 工商银行(01398)发布中期业绩，归母净利润1681.03亿元，同比下降1.4% 都市丽人(02298)发布中期业绩 股东应占溢利5779.6万元 毛利率维持稳定于约46.4% 心动公司(02400)发布中期业绩，股东应占溢利7.55亿元 同比增长268% 龙湖集团(00960)发布中期业绩，收入同比增长25.4%至587.5亿元，运营业务及服务业务核心溢利保持增 长 固生堂(02273)发布中期业绩 股东应占溢利1.52亿元 同比增加41.9% 汇量科技(01860)公布2025中期业绩：收入9.38亿美元，同比大增47% ，旗下Mintegral智能出价表现强劲 同道猎聘(06100)发布中期业绩 股东应占纯利8030万元 同比增长77.13% 累计注册企业用 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company reported a total revenue of 1.495 billion yuan for the first half of 2025, representing a year-on-year growth of 9.5%, and a net profit of 152 million yuan, which is a 41.6% increase year-on-year [1][2] - The operating cash flow reached 300 million yuan, showing a significant increase of 111% year-on-year [1] - The company is focusing on the development of "AI avatars" for renowned doctors, which aims to enhance the quality of traditional Chinese medicine services and improve operational efficiency [3] Summary by Sections Financial Performance - In the first half of 2025, the company's revenue grew to 1.495 billion yuan, with a net profit of 152 million yuan, driven by improved gross margins and effective cost control [2] - The gross margin increased by 1.2 percentage points to 30.6%, while the management expense ratio decreased by 1.8 percentage points to 6.3% [2] - The number of patient visits increased to 2.747 million, with a stable average spending per visit and a member retention rate of 85% [2] Strategic Initiatives - The company is accelerating its national and international expansion, having established 7 new clinics, bringing the total number of global offline medical institutions to 83 by the end of June 2025 [2] - The development of "AI avatars" is expected to alleviate the supply bottleneck of quality traditional Chinese medicine resources and enhance the company's capacity for revenue growth [3] Profit Forecast and Valuation - The adjusted net profit forecasts for 2025, 2026, and 2027 are 493 million yuan, 594 million yuan, and 708 million yuan respectively [3] - The company is expected to benefit significantly from the aging population and supportive policies in the traditional Chinese medicine sector, alongside the advantages brought by AI [3]

Core Insights - The company reported a significant increase in net profit, reaching 150 million yuan, a year-on-year growth of 41.6% [1] - EBITDA reached 270 million yuan, reflecting a year-on-year increase of 37.3%, indicating strong operational efficiency and cost control [1] - The impressive performance is attributed to the dual strategies of cost reduction and business focus, enhancing profitability and operational resilience [1] Financial Performance - Revenue for the first half of 2025 was 1.49 billion yuan, representing a growth of 9.5% [2] - Growth drivers included the "same city expansion + new city development" strategy, with new branches entering profitability and contributing stable revenue [2] - The number of repeat patients increased by 14.8% due to refined operational tools and AI health assistants, further boosting overall performance [2] Profitability and Efficiency - The company's gross profit margin improved to 30.6%, benefiting from a decrease in expense and cost ratios due to scale growth [2] - High-margin self-priced product revenue surged by 209.1%, alongside significant growth in self-funded projects like traditional Chinese medicine therapies [2] - Administrative and sales expense ratios decreased, contributing to the 37.3% growth in EBITDA, showcasing enhanced profitability [2] Future Outlook - The company is positioned to continue delivering high profit growth and quality optimization, supported by national policies promoting the traditional Chinese medicine industry [2]